Skip to main content

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Active, not recruiting · Phase 2 · NCT05451810

Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma

At a glance

Research payments reported, 2025
$2.5M
U.S. investigators named
69
Sites paid
87
Planned or actual enrollment
184

About the trial

Sponsor
Genmab (with AbbVie)
Tested
Epcoritamab (drug)
Dates
Started 2022-08-17; completion 2027-03
Results posted
Not yet

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy including at least 1 anti-CD20 monoclonal antibody-containing therapy or R/R classic follicular lymphoma (cFL). Adverse events will be assessed. Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R cFL. Study doctors …

From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $2.5M in research payments for this study in 2025 (406 payments).

Products named: Epkinly

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.